Testing a combination drug treatment for brain lymphoma

Plain-English translation of NCT06832267 on ClinicalTrials.gov ↗ · Source last updated February 2025 · Translation generated August 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a combination of four chemotherapy drugs called as a first-line treatment for primary central nervous system diffuse large B-cell lymphoma, a cancer that starts in the brain. Researchers want to learn how well this medication works and what side effects patients experience. If the treatment works well, you may then have the option to receive additional therapy or radiation to the brain.

Primary central nervous system lymphoma is a rare cancer, and doctors need better treatment options for patients newly diagnosed with this disease. This trial explores whether this combination of medications can help more patients achieve remission and improve outcomes.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been newly diagnosed with primary central nervous system diffuse large B-cell lymphoma confirmed by a biopsy
you have not received any chemotherapy or cancer treatment before (except steroids to manage symptoms)
you are in reasonably good overall health with a life expectancy of at least three months
you are willing to use birth control during the study and for six months after treatment ends (if of childbearing age)

You likely don't qualify if…

you have previously received chemotherapy or cancer-directed therapy
you have had major surgery in the past three weeks
you have serious heart, lung, kidney, or bleeding disorders that are not well controlled
you have an active infection requiring antibiotics, antifungal, or antiviral medications
you are pregnant, breastfeeding, or unwilling to use contraception during the study

What participation looks like

You would receive four rounds of intravenous chemotherapy, with each cycle lasting 28 days. During each cycle, you'll receive the four medications on specific days through an IV. The treatment will likely require multiple hospital or clinic visits per cycle. After completing the four cycles, if your cancer responds well, you can choose to either receive a stem cell transplant or whole-brain radiation therapy to reduce the risk of the cancer returning.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Trial locations(1 site)

China

Zhejiang Cancer Hospital, Hangzhou, Zhejiang